When was Rhythm Pharmaceuticals founded?

Rhythm Pharmaceuticals was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Rhythm Pharmaceuticals located?

Rhythm Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

Who is the current CEO of Rhythm Pharmaceuticals?

David Meeker of Rhythm Pharmaceuticals.

How many employees does Rhythm Pharmaceuticals have?

As of Apr 30, 2026, the latest employee count at Rhythm Pharmaceuticals is 466.

Is Rhythm Pharmaceuticals a funded company?

Rhythm Pharmaceuticals is a funded company, having raised a total of $84M across 9 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 15, 2010.

When was the latest funding round of Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' latest funding was a $***** Post IPO round on Apr 01, 2024, with participation from 1 investor.

What is the annual revenue of Rhythm Pharmaceuticals?

Annual revenue of Rhythm Pharmaceuticals is $190M as on Dec 31, 2025.

Where does Rhythm Pharmaceuticals rank among its competitors?

Rhythm Pharmaceuticals ranks 20th amongst 302 active competitors, of which 82 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' top competitors include Alnylam, BridgeBio and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Rhythm Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Rhythm Pharmaceuticals is a public company based in Boston (United States), founded in 2010 by Bart Henderson. It operates as a Developer of peptide therapeutics for the treatment of rare genetic deficiencies. Rhythm Pharmaceuticals has raised $84M in funding from Third Rock Ventures and Pfizer Venture Investments. The company has 302 active competitors, including 82 funded and 110 that have exited. Its top competitors include companies like Alnylam, BridgeBio and Alexion.

Company Details

Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.

Email ID: *****@rhythmtx.com
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2010

Location

Boston, United States

Stage

Public

Total Funding

$84M in 9 rounds

Latest Funding Round

Post IPO, Apr 01, 2024, $*****

Investors

Third Rock Ventures & 9 more

Ranked

20^th among 302 active competitors

Annual Revenue

$190M as on Dec 31, 2025

Employee Count

466 as on Apr 30, 2026

Investment & Acquisitions

Xinvento

Similar Companies

Alnylam & 354 more

Exit Details

Public

View Rhythm Pharmaceuticals' full profile

Rhythm Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rhythm Pharmaceuticals, Inc. CIN: 1649904 , United States, Active	Feb 25, 2013	$190M (As on Dec 31, 2025)	-	-
RHYTHM PHARMAEUTICALS CIN: 0798.109.961 , Belgium, Active	Feb 01, 2023	-	-	-
Rhythm Pharmaceuticals Inc CIN: 462159271 , United States, Active	Dec 31, 1999	-	191 (As on Dec 31, 2024)	-

Rhythm Pharmaceuticals got listed on Oct 05, 2017.

Click here to take a look at Rhythm Pharmaceuticals's IPO in detail

Rhythm Pharmaceuticals has raised a total funding of $84M over 9 rounds. Its first funding round was on Mar 15, 2010. Its latest funding round was a Post IPO round on Apr 01, 2024 for $*****. 1 investor participated in its latest round. Rhythm Pharmaceuticals has 10 institutional investors.

Here is the list of recent funding rounds of Rhythm Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2024	2912842	Post IPO	5435500	6063355	3746925	9303576
Feb 16, 2017	9099326	Venture Debt	8020710	8494511	3441193	Deerfield & 4 more
Jul 10, 2015	5274414	Grant (prize money)	4285638	5027377	7738433	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Rhythm Pharmaceuticals's funding rounds and investors

The founders of Rhythm Pharmaceuticals is Bart Henderson. David Meeker is the CEO of Rhythm Pharmaceuticals.

Here are the details of Rhythm Pharmaceuticals' key team members:

Bart Henderson: Former Founder & President of Rhythm Pharmaceuticals and founder of 1 other company.
David Meeker: CEO of Rhythm Pharmaceuticals.
Contact Info: 1 email address

View details of Rhythm Pharmaceuticals's Founder profiles and Board Members

Rhythm Pharmaceuticals' employee count trend

Rhythm Pharmaceuticals has 466 employees as of Apr 26. Here is Rhythm Pharmaceuticals's employee count trend over the years:

Employee count trend for Rhythm Pharmaceuticals

Uncover Rhythm Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rhythm Pharmaceuticals include Alnylam, BridgeBio and Alexion. Here is the list of Top 10 competitors of Rhythm Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Allen & Company & 9 others	79/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	76/100
5th	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	72/100
6th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
7th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
8th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 9 others	70/100
9th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Third Rock Ventures, Flagship Pioneering & 6 others	70/100
10th	Entrada Therapeutics 2016, Boston (United States), Public	Developer of the biologics-based platform to treat rare diseases	$175M	5AM Ventures, Wellington & 11 others	69/100
20th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Deerfield, Foresite Capital & 8 others	70/100